Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995750 | 0.89 | TRPV4 (0.41) | HRH4TRPV4HTR3AHTR6SCN9A | |
| SCHEMBL1994914 | 0.88 | HRH4 (0.46) | HRH4TRPV4HTR3APDE5ACTNNB1 | |
| SCHEMBL1993565 | 0.87 | HRH4 (0.46) | HRH4TRPV4HTR3APDE5ACTNNB1 | |
| SCHEMBL1996846 | 0.81 | HRH4 (0.42) | HRH4KDM4E | |
| SCHEMBL1996847 | 0.81 | HRH4 (0.42) | HRH4KDM4E | |
| SCHEMBL2031142 | 0.78 | HRH4 (0.54) | HRH4HTR3AALDH1A1 | |
| SCHEMBL1990872 | 0.78 | TRPV4 (0.45) | HRH4TRPV4CTNNB1TCF7L2HTR6 | |
| SCHEMBL1990169 | 0.78 | HRH4 (0.47) | HRH4HTR6 | |
| SCHEMBL1990553 | 0.76 | ADRA1A (0.45) | HRH4HTR3AHTR6ALDH1A1 | |
| SCHEMBL1994195 | 0.74 | HRH4 (0.57) | HRH4HTR3APDE5AHTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | HRH4 249/4885TRPV4 241/4885HTR3A 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.